Jandke, Anett http://orcid.org/0000-0002-7681-7952
Melandri, Daisy http://orcid.org/0000-0002-8022-2345
Monin, Leticia http://orcid.org/0000-0002-4951-8105
Ushakov, Dmitry S. http://orcid.org/0000-0001-7109-4217
Laing, Adam G.
Vantourout, Pierre http://orcid.org/0000-0001-7287-5517
East, Philip
Nitta, Takeshi http://orcid.org/0000-0003-2384-3062
Narita, Tomoya
Takayanagi, Hiroshi
Feederle, Regina http://orcid.org/0000-0002-3981-367X
Hayday, Adrian http://orcid.org/0000-0002-9495-5793
Funding for this research was provided by:
Francis Crick Institute (FC001093, FC001093)
EC | Horizon 2020 Framework Programme (792383)
Wellcome Trust (106292/Z/14/Z)
Article History
Received: 5 November 2019
Accepted: 26 June 2020
First Online: 28 July 2020
Competing interests
: A.C.H. is equity holder in GammaDelta Therapeutics and in Adaptate Biotherapeutics. The remaining authors declare no competing interests.